



ASX Announcement

17 December 2018

## **Commercialisation of Animal Health products commences in international markets with Virbac**

### **Highlights:**

- **Creso confirms the first Purchase Order from Virbac global headquarters for its Animal Health products**
- **The A\$350k order follows the successful launch of anibidiol® into the Swiss & Liechtenstein markets late in 2017**
- **Virbac markets and promotes the Creso Animal Health products in Europe and Latin America starting Q2 2019**
- **Further orders into additional countries are planned**

**Creso Pharma Limited** (ASX:CPH, FRA:1X8, the “Company” or “Creso”) confirmed today the first Purchase Order for A\$350,000 from Virbac HQ for its Animal Health products.

The order comes off the back of the exclusive commercialisation agreement signed last month to expand marketing, promotion and distribution of Creso’s Animal Health products into 15 countries in Europe and Latin America following the successful launch in Switzerland and Liechtenstein.

The initial purchase order is for the launch, promotion and distribution of the products by Virbac in several European countries starting Q2 2019.

Said Creso Pharma Co-Founder and Chief Executive Officer Dr. Miri Halperin Wernli: “We have had a promising start with our animal health products in Switzerland and Liechtenstein with very encouraging feedback from veterinarians, clinics and pet owners and we are now entering the expansion phase into many countries in Europe and Latin America.”

Creso and Virbac’s global reach puts them in a unique position to capture market share across the \$69 billion annual pet industry.

- Ends -



**Notes to editors:** Creso Pharma has a portfolio covering five key areas of focus: Creso Therapeutics, Creso Nutraceuticals, Creso Animal Health, Creso Lifestyle and Creso Topicals.

For further information visit [www.cresopharma.com](http://www.cresopharma.com)

### **About Creso Pharma**

[www.cresopharma.com](http://www.cresopharma.com)

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

### **About Virbac**

<https://corporate.virbac.com/home-en.html>

<https://www.virbac.ch/de/>

Virbac is an independent pharmaceutical laboratory dedicated to animal health, since its beginning. Currently the world's 7th largest animal health company with presence in more than 100 countries with more than 4,800 employees and sales subsidiaries in 33 countries. Virbac offers a comprehensive and practical range of products and services covering the majority of species and pathologies.

### **Forward looking statements**

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation. The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.



**Investor & Media Enquiries**

EverBlu Capital

Level 39, Aurora Place 88 Phillip Street, Sydney NSW 2000

E: [info@everblucapital.com](mailto:info@everblucapital.com)

P: +61 2 8249 000